Market News & Trends
PCT Now a Global CDMO as Part of Hitachi Chemical
On May 18, 2017, PCT announced that Hitachi Chemical Co. America, Ltd. (Hitachi Chemical’s consolidated subsidiary) completed its purchase of the 80.1% remaining membership interest…
Stable Economy Will Drive German Pharmaceuticals Market to $86.3 Billion
The German pharmaceuticals market is set to rise from $67.9 billion (€52.9 billion) in 2016 to around $86.3 billion (€67.2 billion) in 2021, representing a…
Catalent Biologics Announces Collaboration With Therachon
Catalent Pharma Solutions recently announced that it has signed an agreement with Therachon AG, a Swiss biotechnology company focused on rare genetic diseases, to support…
InveniAI is Launched With Industry-Leading Artificial Intelligence-Powered R&D Engine
BioXcel Corporation recently announced the formation of InveniAI to focus on maximizing the commercial potential of its proprietary pharma discovery and development engine, EvolverAI, and…
Cinfa Biotech Announces Positive Data for Biosimilar Candidate
Cinfa Biotech S.L., the biosimilars company of Cinfa Group, recently announced positive top-line data from the second clinical trial with its lead development candidate B12019,…
ABITEC’s Facility Expansion Promises New Manufacturing Capabilities
After producing quality products for more than 50 years, ABITEC is now reaping the rewards of a brand new expansion to their central Janesville facility.…
Aptar Pharma’s Electronic Nasal Lockout Device Receives Approved
Aptar Pharma, a world leader in innovative drug delivery systems, recently announced the approval by the European Medicines Agency (EMA) of the first integrated electronic…
First-in-Class Innovation a Key Strategy for Pharmaceutical Companies in a Harsh Market Environment
Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to…
First-in-Class Innovation a Key Strategy for Pharmaceutical Companies in a Harsh Market Environment
Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to…
Thermo Fisher Scientific to Acquire Patheon for $7.2 Billion
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development…
Advances in Continuous Manufacturing of Drug Product, Commercial Spray Drying & HPAPIs/SDD at Hovione
Applying extensive knowledge, data, and a Development by Design (DbD) approach has enabled Hovione to accelerate spray drying development; reducing cost and time to get…
Sekisui XenoTech Awarded Cryopreservation Patent, Achieves Numerous Hepatocyte Enhancements
Sekisui XenoTech was recently issued US Patent No. 9,642,355 for the cryopreservation of cells and subcellular fractions,” specifically related to Sekisui XenoTech’s CryostaX test systems,…
Immunocore Identifies Second Novel ImmTAC in GSK Collaboration
Immunocore Limited recently announced it has identified a lead compound in its second discovery program with GSK. This novel ImmTAC lead molecule is relevant in…
Thermo Fisher Scientific to Acquire Patheon for $7.2 Billion
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development…
Dauntless Pharmaceuticals Announces Positive Data
Dauntless Pharmaceuticals, Inc. recently announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration.…
Feldan Therapeutics & Elasmogen Announce Research Agreement With Amgen
Elasmogen Ltd and Feldan Therapeutics recently announced a research collaboration with Amgen to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities…
Dalton Pharma Services Signs Development & Manufacturing Agreement
Dalton Pharma Services, a leading pharmaceutical cGMP contract manufacturing company, recently announced the signing of a drug development and manufacturing services agreement with Arch Biopartners,…
Adamas Signs $100-Million Royalty-Backed Note Agreement
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) recenbtly announced that it has entered into a $100-million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the…
Adamas Signs $100-Million Royalty-Backed Note Agreement
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) recenbtly announced that it has entered into a $100-million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the…
Lupin Announces Opening of New Expansion at its NJ Manufacturing Site
The leadership of Lupin Limited gathered along with state and local leaders, including Rep. Bonnie Watson Coleman (DNJ – 12th District), to celebrate the grand…
